Elafibranor

• Description:

  Elafibranor (GFT505) is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively. Elafibranor can be used for the study of primary biliary cholangitis[1].

• Product Name Alternative:

  GFT505

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  PPAR

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Elafibranor.html

• Purity:

  99.66

• Solubility:

  DMSO : ≥ 33 mg/mL

• Smiles:

  CC(C)(OC1=C(C)C=C(/C=C/C(C2=CC=C(SC)C=C2)=O)C=C1C)C(O)=O

• Molecular Formula:

  C22H24O4S

• Molecular Weight:

  384.49

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Liu ZM, et al. Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.Expert Opin Investig Drugs. 2015 May;24 (5) :611-21.|[2]Ratziu V, et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016 May;150 (5) :1147-1159.|[3]Hanf R, et al. The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.Diab Vasc Dis Res. 2014 No

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  PPARα; PPARβ/δ

• CAS Number:

  923978-27-2